CytoAgents Receives Third Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

CytoAgents Inc., a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the third NIH grant in four years. This funding will accelerate the development of its lead drug candidate, CTO1681, an investigational new drug that uses a novel approach designed to prevent and mitigate Cytokine Release Syndrome in patients receiving CAR T-Cell therapy. This is an area of great unmet medical need as the majority of patients undergoing CAR T treatment for their cancer experience CRS and associated neurotoxicity. Read more >>